Healey ALS Platform Trial - Regimen F ABBV-CLS-7262
Not Recruiting
18-100 years
All
Phase
2
2 participants needed
1 Location
Brief description of study
ABBV-CLS-7262 is a prodrug that is converted in vivo to the pharmacologically active parent compound A-1684909. A-1684909 is a central nervous system (CNS)-penetrant, eukaryotic translation initiation factor 2B (eIF2B) activator that attenuates the integrated stress response (ISR), a highly conserved cellular mechanism hypothesized to be important in the pathophysiology of amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions when activated chronically (Costa-Mattioli et al. 2020).
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Amyotrophic Lateral Sclerosis,ALS
-
Age: Between 18 Years - 100 Years
-
Gender: All
Confirmed ALS diagnosis; greater than 50% FVC or SVC; less than 36 months since symptom onset; must either be not taking, or on a stable dose of Riluzole, Edaravone (Radicava), or Relyvrio
Updated on
13 May 2024.
Study ID: 842770F
